Photodynamic therapy of malignant glioma with hypericin: Comprehensive in vitro study in human glioblastoma cell lines

International Journal of Oncology

Volumn 30, Issue 3, 2007, Pages 659-667

  Ritz, Rainer ^a   Wein, Hannah T ^a   Dietz, Klaus ^a   Schenk, Martin ^a   Roser, Florian ^a   Tatagiba, Marcos ^a   Strauss, Wolfgang S L ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Glioblastoma cells; Hypericin; Photodynamic therapy

Indexed keywords

DRUG DERIVATIVE; HYPERICIN; PERYLENE; PHOTOSENSITIZING AGENT;

ARTICLE; BRAIN TUMOR; CELL MEMBRANE; CHEMISTRY; FLUORESCENCE MICROSCOPY; GLIOBLASTOMA; GLIOMA; HUMAN; LIGHT; METABOLISM; METHODOLOGY; PHOTOCHEMOTHERAPY; TIME; TUMOR CELL LINE;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; GLIOBLASTOMA; GLIOMA; HUMANS; LIGHT; MICROSCOPY, FLUORESCENCE; PERYLENE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TIME FACTORS;

EID: 33947714278     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.3.659     Document Type: Article

References (54)

1. Dougherty T, Gomer C, Henderson B, Jori G, Kessel D, Korbelik M, Moan J and Peng Q: Photodynamic therapy. J Natl Cancer Inst 90: 889-905, 1998.
2. Tang J, Colacino JM, Larsen SH and Spitzer W: Virucidal activity of hypericin against enveloped and non-enveloped DNA and RNA viruses. Antiviral Res 13: 313-325, 1990.
3. Gupta V, Su Y, Wang W, Kardosh A, Liebes L, Hofman F, Schonthal A and Chen TC: Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. Neurosurg Focus 20: E20, 2006.
4. Martinez-Poveda B, Quesada AR and Medina MA. Hypericin in the dark inhibits key steps of angiogenesis in vitro. Eur J Pharmacol 516: 97-103, 2005.
5. Agostinis P, Vantieghem A, Merlevede W and De Witte PA: Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol 34: 221-241, 2002.
6. Diwu Z and Lown JW: Photosensitization with anticancer agents. EPR studies of photodynamic action of hypericin: formation of semiquinone radical and activated oxygen species on illumination. Free Radic Biol Med 14: 209-215, 1993.
7. Ehrenberg B, Anderson JL and Foote CS: Kinetics and yield of singlet oxygen photosensitized by hypericin in organic and biological media. Photochem Photobiol 68: 135-140, 1998.
8. Hadjur C, Richard MJ, Parat MO, Favier A and Jardon P: Photodynamically induced cytotoxicity of hypericin dye on human fibroblast cell line MRC5. J Photochem Photobiol B 27: 139-146, 1995.
9. Thomas C and Pardini RS: Oxygen dependence of hypericin-induced phototoxicity to EMT6 mouse mammary carcinoma cells. Photochem Photobiol 55: 831-837, 1992.
10. Vandenbogaerde AL, Cuveele JF, Proot P, Himpens BE, Merlevede WJ and De Witte PA: Differential cytotoxic effects induced after photosensitization by hypericin. J Photochem Photobiol B 38: 136-142, 1997.
11. Ali SM and Olivo M: Bio-distribution and subcellular localization of Hypericin and its role in PDT induced apoptosis in cancer cells. Int J Oncol 21: 531-540, 2002.
12. Kamuhabwa AR, Agostinis PM, D'Hallewin MA, Baert L and De Witte PA: Cellular photodestruction induced by hypericin in AY-27 rat bladder carcinoma cells. Photochem Photobiol 74: 126-132, 2001.
13. Blank M, Kostenich G, Lavie G, Kimel S, Keisari Y, and Orenstein A: Wavelength-dependent properties of photodynamic therapy using hypericin in vitro and in an animal model. Photochem Photobiol 76: 335-340, 2002.
14. Liu CD, Kwan D, Saxton RE and McFadden DW: Hypericin and photodynamic therapy decreases human pancreatic cancer in vitro and in vivo. J Surg Res 93: 137-143, 2000.
15. Kamuhabwa AR, Agostinis P, D'Hallewin MA, Kasran A and De Witte PA: Photodynamic activity of hypericin in human urinary bladder carcinoma cells. Anticancer Res 20: 2579-2584, 2000.
16. Uzdensky AB, Ma LW, Iani V, Hjortland GO, Steen HB and Moan J: Intracellular localisation of hypericin in human glioblastoma and carcinoma cell lines. Lasers Med Sci 16: 276-283, 2001. (Pubitemid 33000663)
17. Couldwell WT, Gopalakrishna R, Hinton DR, He S, Weiss MH, Law RE, Apuzzo ML and Law RE: Hypericin: a potential antiglioma therapy. Neurosurgery 35: 705-709, 1994.
18. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lutolf UM and Kleihues P: Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899, 2004.
19. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
20. Bashir R, Hochberg F and Oot R: Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 23: 27-30, 1988.
21. Stummer W, Novotny A, Stepp H, Goetz C, Bise K and Reulen HJ: Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93: 1003-1013, 2000. (Pubitemid 32800611)
22. Stummer W, Pichlmeier U, Meinel T, Wiestler O, Zanella F, Reulen HJ and ALA-Glioma Study Group: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7: 392-401, 2006.
23. Duffner F, Ritz R, Freudenstein D, Weller M, Dietz K and Wessels J: Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX. J Neurooncol 71: 107-111, 2005. (Pubitemid 40796290)
24. Wu S, Ren Q, Zhou M, Peng Q and Chen J: Protoporphyrin IX production and its photodynamic effects on glioma cells, neuroblastoma cells and normal cerebellar granule cells in vitro with 5-aminolevulinic acid and its hexyleste. Cancer Lett 200: 123-131, 2003.
25. Stummer W, Stocker S, Novotny A, Heimann A, Sauer O, Kempsk O, Plesnila N, Wietzorrek J and Reulen HJ: In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid. J Photochem Photobiol B 45: 160-169, 1998.
26. Hebeda K, Saarnak A, Olivo M, Sterenborg H and Wolbers JG: 5-Aminolevulinic acid induced endogenous fluorescence in 9L and c6 brain tumours and in normal rat brain. Acta Neurochir 140: 503-512, 1998. (Pubitemid 28312798)
27. Hirschberg H, Sun C-H, Tromberg BJ and Madsen S: ALA- and ALA-esters-mediated phototdynamic therapy of human glioma spheroids. J Neurooncol 57: 1-7, 2002. (Pubitemid 34692608)
28. Madsen SJ, Sun CH, Tromberg BJ, Wallace VP and Hirschberg H: Photodynamic therapy of human glioma spheroids using 5-aminolevulinic acid. Photochem Photobiol 72: 128-134, 2000.
29. Angell-Petersen E, Spetalen S, Madsen S, Sun C, Peng Q, Carper S, Sioud M and Hirschberg H: Influence of light fluence rate on the effects of photodynamic therapy in an orthopic rat glioma model. J Neurosurg 104: 109-117, 2006. (Pubitemid 43304352)
30. Hirschberg H, Sorensen D, Angell-Petersen E, Peng Q, Tromberg B, Sun C, Spetalen S and Madsen S: Repetive photodynamic therapy of malignant brain tumors. J Environ Pathol Toxicol Oncol 25: 261-280, 2006. (Pubitemid 43341246)
31. Ito S, Rachinger W, Stepp H, Reulen HJ and Stummer W: Oedema formation in experimental photo-irradiation of brain tumors using 5-ALA. Acta Neurochir 147: 57-65, 2005.
32. Olzowy B, Hundt C, Stocker S, Bise K, Reulen HJ and Stummer W: Photoirradiation therapy of experimental malignant glioma with 5-aminolevulinic acid. J Neurosurg 97: 970-976, 2002. (Pubitemid 35222423)
33. Ritz R, Müller M, Weller M, Dietz K, Kuci S, Roser F and Tatagiba M: Hypericin: a promising fluorescence marker for differentiating between glioblastoma and neurons in vitro. Int J Oncol 27: 1543-1549, 2005.
34. Fautrel A, Chesné C, Guillouzo A, De Sousa G, Placidi M, Rahmani R, Braut F, Pichon J, Hoellinger H, Vintézou P, Diarte I, Melcion C, Cordier A, Lorenzon G, Benicourt M, Vannier B, Fournex R, Peloux AF, Bichet N, Gouy D, Cano JP and Lounes R: A multicentre study of acute in vitro cytotoxicity in rat liver cells. Toxicol in Vitro 5: 543-547, 1991.
35. Stock K, Sailer R, Strauss W, Lyttek M, Steiner R and Schneckenburger H: Variable-angle total internal reflection fluorescence microscopy (VA-TIRFM); realization and application of a compact illumination device. J Microsc 211: 19-29, 2003.
36. Huygens A, Huyghe D, Bormans G, Verbruggen A, Kamuhabwa AR, Roskams T and De Witte PA: Accumulation and photocytotoxicity of hypericin and analogs in two- and three-dimensional cultures of transitional cell carcinoma cells. Photochem Photobiol 78: 607-614, 2003.
37. Theodossiou T, Spiro MD, Jacobson J, Hothersall JS and Macrobert AJ: Evidence for intracellular aggregation of hypericin and the impact on its photocytotoxicity in PAM 212 murine keratinocytes. Photochem Photobiol 80: 438-443, 2004.
38. Sattler S, Schaefer U, Schneider W, Hoelzl J and Lehr CM: Binding, uptake, and transport of hypericin by Caco-2 cell monolayers. J Pharm Sci 86: 1120-1126, 1997.
39. Weber ND, Murray BK, North JA and Wood SG: The antiviral agent hypericin has in vitro activity against HSV-1 through non-specific association with viral and cellular membranes. Antiviral Chem Chemother 5: 83-90, 1994.
40. Vandenbogaerde AL, Delaey EM, Vantieghem AM, Himpens BE, Merlevede WJ and De Witte PA: Cytotoxicity and antiproliferative effect of hypericin and derivatives after photosensitization. Photochem Photobiol 67: 119-125, 1998.
41. Delaey EM, Obermueller R, Zupko I, De Vos D, Falk H and De Witte PA: In vitro study of the photocytotoxicity of some hypericin analogs on different cell lines. Photochem Photobiol 74: 164-171, 2001.
42. Siboni G, Weitman H, Freeman D, Mazur Y, Malik Z and Ehrenberg B: The correlation between hydrophilicity of hypericins and helianthrone: internalization mechanisms, subcellular distribution and photodynamic action in colon carcinoma cells. Photochem Photobiol Sci 1: 483-491, 2002.
43. Kascakova S, Refregiers M, Jancura D, Sureau F, Maurizot JC and Miskovsky P: Fluorescence spectroscopic study of hypericin-photosensitized hxidation of how-density hipoproteins. Photochem Photobiol 81: 1395-1403, 2005.
44. Miskovsky P, Hritz J, Sanchez-Cortes S, Fabriciova G, Ulicny J and Chinsky L: Interaction of hypericin with serum albumins: surface-enhanced Raman spectroscopy, resonance Raman spectroscopy and molecular modeling study. Photochem Photobiol 74: 172-183, 2001.
45. Maletinska L, Blakely EA, Bjornstad KA, Deen DF, Knoff LJ and Forte TM: Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res 60: 2300-2303, 2000.
46. Li Y, Cam J and Bu G: Low-density lipoprotein receptor family: endocytosis and signal traduction. Mol Neurobiol 23: 53-67, 2001.
47. Moan J and Berg K: The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 53: 549-553, 1991.
48. Miccoli L, Beurdeley-Thomas A, De Pinieux G, Sureau F, Oudard S, Dutrillaux B and Poupon MF: Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria. Cancer Res 58: 5777-5786, 1998.
49. Johnson SA and Pardini RS: Antioxidant enzyme response to hypericin in EMT6 mouse mammary carcinoma cells. Free Radic Biol Med 24: 817-826, 1998.
50. Theodossiou T, Noronha-Dutra A and Hothersall JS: Mitochondria are a primary target of hypericin phototoxicity: synergy of intracellular calcium mobilsation in cell killing. Int J Biochem Cell Biol 38: 1946-1956, 2006.
51. Hadjur C, Richard MJ, Parat MO, Jardon P and Favier A: Photodynamic effects of hypericin on lipid peroxidation and antioxidant status in melanoma cells. Photochem Photobiol 64: 375-381, 1996.
52. Chaloupka R, Obsil T, Plasek J and Sureau F: The effect of hypericin and hypocrellin-A on lipid membranes and membrane potential of 3T3 fibroblasts. Biochim Biophys Acta 1418: 39-47, 1999.
53. Zhang W, Law RE, Hinton DR and Couldwell WT: Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor. Cancer Lett 120: 31-38, 1997.
54. Blank M, Lavie G, Mandel M, Hazan S, Orenstein A, Meruelo D and Keisari Y: Antimetastatic activity of the photodynamic agent hypericin in the dark. Int J Cancer 111: 596-603, 2004.